Can you take Enzalutamide with Repotrectinib?

Repotrectinib has a moderate potential interaction with Asthma.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

Enzalutamide has a moderate potential interaction with Brain Tumor.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Enzalutamide has a moderate potential interaction with CNS Infection.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Repotrectinib has a moderate potential interaction with COPD.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

Enzalutamide has a moderate potential interaction with Head Injury.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Enzalutamide has a moderate potential interaction with History - Cerebrovascular Disease.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.

Repotrectinib has a moderate potential interaction with Interstitial Lung Disease.

Repotrectinib can cause interstitial lung disease (ILD)/pneumonitis. This may be considered in patients with lung or breathing problems other than lung cancer. Patients should be monitored for new/worsening pulmonary symptoms indicative of ILD/pneumonitis and should be advised to contact their health care provider if such symptoms develop.

Repotrectinib has a moderate potential interaction with Liver Disease.

Repotrectinib can cause hepatotoxicity; this may be considered in patients with liver problems. The effect of moderate or severe liver dysfunction (total bilirubin greater than 1.5 times the upper limit of normal and any AST) on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with moderate or severe liver dysfunction.

Repotrectinib has a moderate potential interaction with Neurological Disorders.

Repotrectinib can cause central nervous system (CNS) adverse reactions including dizziness, ataxia, cognitive disorders, mood disorders, and sleep disorders. This may be considered in patients with neurological problems. Patients should be advised to contact their health care provider for new/worsening CNS symptoms.

Enzalutamide has a moderate potential interaction with Renal Dysfunction.

Enzalutamide has not been assessed in patients with severe renal impairment or end-stage renal disease. Caution is advised if used on these patients. No initial dosage adjustment is required on patients with mild to moderate renal impairment.

Repotrectinib has a moderate potential interaction with Renal Dysfunction.

The effect of severe renal dysfunction, kidney failure (estimated GFR less than 30 mL/min), or dialysis on repotrectinib pharmacokinetics is unknown. The recommended dosage of repotrectinib has not been established in patients with severe renal dysfunction or kidney failure or in patients on dialysis.

Enzalutamide has a moderate potential interaction with Seizures.

Seizures occurred in 0.5% of patients receiving enzalutamide in clinical trials. Patients with predisposing factors for seizures were generally excluded. Caution is advised if using in patients with possible predisposing factors such as history of seizures, history of trauma or head injury, cerebrovascular accident or transient ischemic attack, Alzheimer's disease, meningioma or brain tumor or infection, and any unexplained loss of consciousness in the past 12 months. Enzalutamide should be discontinued permanently in any patient who develops a seizure during treatment.